Single-DoseOralPharmacokineticsofPergolide MesylateinHealthyAdultMares*

Ronette Gehring,Laurie A. Beard,Johann F. Coetzee,Michael D. Apley,R. Gehring,L. A. Beard,Abra Wright,Johann F. Coetzee,James A. Havel,M. D. Apley

Single-DoseOralPharmacokineticsofPergolide MesylateinHealthyAdultMares*

2010

Ronette Gehring
Laurie A. Beard
Johann F. Coetzee
Michael D. Apley
R. Gehring
L. A. Beard
Abra Wright
Johann F. Coetzee
James A. Havel
M. D. Apley

Pituitaryparsintermediadysfunction(PPID)isprobablythemostcommondis -easeofgeriatrichorses.Affectedhorsesshowavarietyofclinicalsigns,includ -ing hirsutism, polyuria/polydipsia, immunosuppression, muscle wasting, andlaminitis.ThemostcommontreatmentforPPIDispergolide,adopamineago -nist;however,therearenopharmacokineticdataabouttheuseofthisdruginhorses.Thisarticledescribesastudydesignedtoaddressthiscompletelackofpharmacokinetic information. The pharmacokinetics of pergolide are describedinasmallgroupofrelativelyyoung,healthymares(

Keywords:

Polyuria
Pergolide
hirsutism
Polydipsia
Wasting
Immunosuppression
Internal medicine
Diabetes mellitus
Endocrinology
Medicine
Urology
Pharmacokinetics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations